|
시장보고서
상품코드
2075128
호산구성 식도염 시장 : 약제 클래스별, 유통 채널별, 지역별 규모, 점유율, 전망 및 기회 분석(2025-2032년)Eosinophilic Esophagitis Market, by Drug Class, by Distribution Channel, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032 |
||||||
호산구성 식도염 시장은 2026년에 3억 1,940만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 24억 2,680만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 33.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 3억 1,940만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 33.60% | 2033년 시장 규모 예측 : | 24억 2,680만 달러 |
호산구 식도염은 스테로이드나 프로톤 펌프 억제제 등의 산 분비 억제제를 사용하여 치료하는 만성질환입니다. 스테로이드는 염증을 억제하는 데 도움이 됩니다. 국소 스테로이드는 흡입제나 액제 형태로 투여됩니다. 심각한 연하 장애나 체중 감소가 있는 환자에게는 경구용 스테로이드가 처방되는 경우가 있습니다. 프로톤 펌프 억제제는 역류 증상을 완화하고 염증을 줄이는 데 도움이 됩니다.
시장 역학
호산구 식도염에 대한 인식이 높아짐에 따라 치료제에 대한 수요가 증가하고 있습니다. 따라서 주요 시장 참여자들은 새로운 치료법 개발에 매진하며, EoE 치료제에 대한 수요에 부응하고자 하고 있습니다. 예를 들어 세계적인 바이오의약품 기업인 사노피는 '듀피센트(듀필루맙)'의 3상 임상시험을 진행 중이며, 2024년까지 완료될 전망입니다. 또한 EoE 관리를 개선하는 혁신적인 신제품의 등장이 세계 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2021년 12월, 일본의 다국적 제약 기업인 다케다 제약 주식회사는 호산구 식도염 치료제인 TAK-721(부데소니드 경구 현탁액)에 대해 미국 식품의약국(FDA)으로부터 완전 답변서(CRL)를 접수했습니다. 2021년 6월, 미국 FDA는 에트라시모드에 대해 희귀질환 치료제 지정(ODD)을 부여했습니다. 에트라시모드는 미국의 바이오의약품 기업인 아레나 파마슈티컬스(Arena Pharmaceuticals)가 연구를 진행해 왔습니다. 또한 호산구 식도염의 유병률 증가 역시 시장 성장을 지원할 가능성이 있습니다. 예를 들어 2018년 7월 '사우디 메디컬 저널'에 게재된 연구에 따르면 호산구 식도염은 신종 질환이며, 사우디아라비아 소아에서 발병률이 증가하는 추세에 있습니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 호산구 식도염 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 호산구 식도염 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 호산구 식도염 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 호산구성 식도염 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 호산구성 식도염 시장 : 유통 채널별, 2021-2033년
제6장 세계의 호산구성 식도염 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 애널리스트의 제안
제9장 섹션
KSA 26.07.07Eosinophilic Esophagitis Market is estimated to be valued at USD 319.4 Mn in 2026 and is expected to reach USD 2,426.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 33.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 319.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 33.60% | 2033 Value Projection: | USD 2,426.8 Mn |
Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.
Market Dynamics
Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global eosinophilic esophagitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis
Detailed Segmentation:
- Global Eosinophilic Esophagitis Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Corticosteroids
- Budesonide
- Jorveza
- Off-label budesonide
- Fluticasone
- Budesonide
- Proton Pump Inhibitor (PPI)
- Omeprazole
- Esomeprazole
- Others
- Late Stage Pipeline Drugs
- Dupixent
- APT-1011
- Lirentelimab (AK002)
- Cendakimab
- Etrasimod
- TAK-721
- Omilancor (BT-11)
- Global Eosinophilic Esophagitis Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Eosinophilic Esophagitis Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- Company Profiles
- GlaxoSmithKline plc*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ellodi Pharmaceuticals
- EsoCap AG
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Dr. Falk Pharma GmbH
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Recent Product Approval/Launch
- PEST Analysis
- Epidemiology
4. Global Eosinophilic Esophagitis Market, By Drug Class, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Budesonide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Jorveza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Off-label budesonide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Jorveza
- Fluticasone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Budesonide
- Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Omeprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Esomeprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Omeprazole
- Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Dupixent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- APT-1012
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Lirentelimab (AK002)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Cendakimab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Etrasimod
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- TAK-721
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Omilancor (BT-11)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Dupixent
5. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Eosinophilic Esophagitis Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2029 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Ellodi Pharmaceuticals.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- EsoCap AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arena Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Revolo Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Allakos Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Bristol-Myers Squibb Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Calypso Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- DBV Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Landos Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alkem Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Quorum Innovations LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Falk Pharma GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Ellodi Pharmaceuticals.
8. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. Section
- References
- Research Methodology
- About Us and Sales Contact
